What's in Stefan Fischli's pipeline?

Stefan Fischli has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Stefan Fischli's portfolio?

Top competitors by shared drug class: , Centre for Addiction and Mental Health, Fougera, Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/stefan-fischli.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Stefan Fischli — Portfolio Competitive Intelligence Brief

Stefan Fischli pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cynara Scolymus	Cynara Scolymus	marketed	Nitrate Vasodilator [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Centre for Addiction and Mental Health · 1 shared drug class
Fougera · 1 shared drug class
Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stefan Fischli:

Cite this brief

Drug Landscape (2026). Stefan Fischli — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stefan-fischli. Accessed 2026-05-16.